MEDG Medgenics(Regs)

 
TIDMMEDG 
 
Medgenics, Inc. 
                         ('Medgenics' or the 'Company') 
 
 
16 June 2009 
 
The Board of Directors of Medgenics are pleased to announce that the resolutions 
proposed  in  its  12 May 2009 request for Written Consent to  Stockholders,  as 
announced  on 11 May 2009, were duly adopted by the holders of at least  75%  of 
the  issued and outstanding shares of common stock in the Company of US  $0.0001 
par value per share effective on June 4, 2009.  A notice to this effect has been 
sent  to  shareholders,  a copy of which is available on the  Company's  website 
(www.medgenics.com). 
 
The  Board  is confident that the first series of the proposed fund raising  (as 
announced on 11 May 2009) will soon be completed and expects to be able to  make 
an  announcement  to  this effect  shortly.  The first series of fund raising is 
expected to raise approximately US $250,000 with further fund raising of  up  to 
US $5million in aggregate still ongoing. 
 
 
For further information, contact: 
 
Medgenics, Inc.                                   +972 4 902 8900 
Dr. Andrew L. Pearlman 
 
Blomfield Corporate Finance (Nominated adviser)   +44 207 489 4500 
James Pinner or 
Alan MacKenzie 
 
SVS Securities plc (Broker)                       +44 207 638 5600 
Ian Callaway 
 
Grayling Global                                   +44 207 255 5406 
Jonathan Shillington or 
Alistair Scott 
 
NOTES TO EDITORS: 
 
Medgenics,  Inc.  is a clinical-stage biopharmaceutical company  developing  its 
unique  tissue-based  Biopump  platform technology to  provide  sustained-action 
protein therapy for the treatment of a range of chronic diseases. 
 
Medgenics currently has two products in development based on this technology: 
 
·    EPODURE - producing erythropoietin (EPO) to treat anemia 
·    INFRADURE - producing interferon-alpha (IFN-a) to treat Hepatitis-C 
 
The  Company's ongoing Phase I/II clinical trial for EPODURE in anemic  patients 
continues  to demonstrate proof of concept of the Biopump.  Designed to  produce 
and  deliver  a therapeutic dose of EPO steadily for up to six months  or  more, 
EPODURE  Biopumps  are already maintaining effective anemia treatment  for  more 
than  5  months  in earliest patients in the ongoing study, even with  low  dose 
administered. 
 
Medgenics  intends to develop its innovative products and bring them  to  market 
via  multiple  strategic partnerships with major pharmaceutical  and/or  medical 
device companies, starting with EPODURE and INFRADURE. 
 
Medgenics plans to raise the requisite funds during 2009 to enable it to  follow 
the  current trial of EPODURE with a Phase IIb clinical trial in the US starting 
in  2010,  and  in  addition, to commence a Phase I/II  trial  of  INFRADURE  in 
Hepatitis-C patients in Israel also during 2010. 
 
Beyond these, Medgenics plans to develop and/or out-license a pipeline of future 
Biopump  products targeting the large and rapidly growing global protein therapy 
market, which is forecast to reach US $87 billion by 2010. Other potential areas 
include  multiple sclerosis (interferon-a), hemophilia (Factor VIII),  pediatric 
growth hormone deficiency (human growth hormone) and diabetes (insulin). 
 
Founded in 2000, Medgenics is a US-incorporated company with major operations in 
Misgav, Israel. Medgenics was admitted to the London AIM in December 2007  (AIM: 
MEDG and AIM: MEDU). 
 
www.medgenics.com 
 
CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS 
This  release contains forward-looking statements, which include all  statements 
other  than statements of historical fact, including (without limitation)  those 
regarding  the  Company's  financial  position,  business  strategy,  plans  and 
objectives  of  management  for future operations. These  statements  relate  to 
future   events,   prospects,   developments  and  strategies.   Forward-looking 
statements  are sometimes identified by their use of the terms and phrases  such 
as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning, 
"expect," "believe," "will," "will likely," "should," "could," "would," "may" or 
the  negative of such terms and other comparable terminology. All such  forward- 
looking  statements are based on current expectations and are subject  to  risks 
and  uncertainties. Should any of these risks or uncertainties  materialize,  or 
should  any  of  the Company's assumptions prove incorrect, actual  results  may 
differ  materially from those included within these forward-looking  statements. 
Accordingly,  no  undue  reliance  should be  placed  on  these  forward-looking 
statements,  which  speak  only  as  of the date  made.  The  Company  expressly 
disclaims  any obligation or undertaking to disseminate any updates or revisions 
to  any forward-looking statements contained herein to reflect any change in the 
Company's  expectations with regard thereto or any change in events,  conditions 
or  circumstances on which any such statements are based. As a result  of  these 
factors,  the  events described in the forward-looking statements  contained  in 
this release may not occur. 
 

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024